Company / Cash & Equivalents
Fortrea Cash & Equivalents History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$174.6M
FY2025
5-year range
$108.6M / $174.6M
FY2022-FY2025
Trend
+47.3%
vs FY2024
Sector context
#98 of 207
Health Care
What the data says
At $175M, Fortrea's cash & equivalents ranks #98 of 207 in the Health Care sector. Improved from $109M to $175M over the past 2 years.
Based on SEC 10-K filings.
$175M in FY2025 with a 3-year CAGR of +16.0%.
Improved from $109M to $175M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +16.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#98 of 207 in Health CareTop 47% of 207This company $174.6M Sector average $669.5M
▼
-73.9% below sector average
Key checks
Key Insights
- 3-year CAGR of +16.0%, indicating consistent growth.
- In FY2025, cash & equivalents increased 47.3% year-over-year.
- Ranks #98 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.32 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $174.6M | +47.3% |
| FY2024 | $118.5M | +9.1% |
| FY2023 | $108.6M | -3.0% |
| FY2022 | $112.0M | - |
| FY2021 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026